Precision Microwave

PUBLIC

Name	Precision Microwave
Tagline	Develops directional microwave ablation tools for minimally invasive cancer treatments
Headquarters	Manhattan, Kansas, USA
Founded	2017
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Undisclosed

Links

PUBLIC

• Website: http://www.precisionmicrowavemedical.com
• LinkedIn: https://www.linkedin.com/company/precision-microwave-medical

Executive Summary

PUBLIC

Precision Microwave is developing directional microwave ablation tools to enable more precise, minimally invasive treatments for solid tumors, a technical approach that could address a persistent limitation in interventional oncology [MedCity News, 2021]. Founded in 2017, the Kansas-based startup is attempting to commercialize a side-firing applicator designed to radiate energy within a controlled 120-180 degree arc, potentially allowing physicians to ablate tumors while sparing adjacent healthy tissue [MedCity News, 2021]. The company's founders, Austin Pfannenstiel and Punit Prakash, are inventors on patents licensed to the venture and have secured backing from regional investor InvestMidwest, though the specific terms of any funding round remain undisclosed [F6S].

Public traction is limited, with third-party estimates placing the company in a pre-revenue or early-revenue state with fewer than 25 employees [ZoomInfo]. The primary near-term catalyst for investor evaluation will be the progression of its technology through the regulatory pathway, a process that has not yet been documented in public filings or announcements. Over the next 12-18 months, visibility into clinical partnerships, prototype validation data, or a clear FDA submission strategy will be necessary to move the venture beyond its current stealth-stage profile.

Data Accuracy: YELLOW -- Core technology claims are cited in a single trade publication; company details are sparse and partially inferred from third-party databases.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)

Company Overview

PUBLIC

Precision Microwave was founded in 2017 in Manhattan, Kansas, as a medical device venture focused on microwave ablation technology [F6S]. The company’s early development was supported by academic roots at Kansas State University, where co-founder Austin Pfannenstiel won first place in the university’s Launch a Business Program the same year [K-State ECE Uplink, 2017]. This initial validation provided a foundation for the technical work that followed.

Key operational milestones are sparse in the public record. The company secured backing from the regional investor InvestMidwest, though the terms and amount of this investment remain undisclosed [F6S]. A notable technical partnership was formed with product development firm Engenious Design, which reportedly delivered a functional demonstration unit for the company’s directional ablation technology within three months for an approximate cost of $200,000 [Medical Device News Magazine]. In 2021, the company won the MedCity INVEST Pitch Perfect competition, a signal of early-stage interest from healthcare investors [MedCity News, 2021].

Beyond these events, the company’s corporate trajectory is lightly documented. No subsequent funding rounds, regulatory clearances, or commercial partnerships have been announced in available sources since the 2021 pitch competition win. The founders are listed as inventors on patents owned and licensed by the company, and co-founder Punit Prakash is noted as a sub-award principal investigator on a National Science Foundation grant, indicating ongoing research activity [PMC].

Data Accuracy: YELLOW -- Founding date and investor confirmed by one source; milestones are cited but lack independent corroboration.

Product and Technology

MIXED Precision Microwave’s public proposition centers on a hardware device for a specific surgical niche: a directional microwave ablation (DMWA) applicator. The core claim is that its tool radiates energy in a 120- to 180-degree radius around the applicator, enabling targeted ablation of tumors while sparing adjacent healthy tissue [MedCity News, 2021]. This side-firing capability is positioned as a technical differentiator from existing omnidirectional ablation devices.

Available details on the product’s development status are sparse. The company has partnered with Engenious Design, a product development firm, which reportedly built a functional demo unit in approximately three months for about $200,000 [Medical Device News Magazine] [Medgadget, 2022]. The company’s specialization is listed as microwave antenna design, optimization, multi-physics modeling, bench testing, and animal evaluation [F6S]. Founders Austin Pfannenstiel and Punit Prakash are listed as inventors on patents owned and licensed by the company, and Prakash is noted as a sub-award principal investigator on a National Science Foundation grant (IIP 1951186) related to the technology [PMC].

No commercial product name, regulatory clearance status, or specific technical specifications (e.g., power output, frequency) are publicly disclosed. The technology remains in a pre-clinical or prototype stage, with no announced partnerships with medical institutions or surgeons for clinical trials.

Data Accuracy: YELLOW -- Core product claim is cited in a single trade publication; development partnership and grant details are corroborated. No independent technical validation or product demo footage is available.

Market Research

PUBLIC

The market for minimally invasive tumor ablation is driven by a persistent clinical need for alternatives to surgery, particularly for tumors in anatomically complex locations where traditional techniques carry high risk.

Third-party market sizing specific to directional microwave ablation is not publicly available. However, analogous market reports for the broader thermal ablation sector provide a useful frame of reference. The global market for thermal ablation systems for cancer treatment was valued at approximately $1.2 billion in 2022 and is projected to grow at a compound annual rate of 11.5% through 2030, according to a report from Grand View Research [Grand View Research, 2023]. This growth is segmented by technology, with microwave ablation representing one of the faster-growing modalities due to perceived advantages in heating efficiency and treatment speed over radiofrequency ablation.

Key demand drivers are well-documented in adjacent medical device literature. The aging global population and rising incidence of cancers like those in the liver, lung, and kidney create a steady procedural volume. A significant tailwind is the ongoing shift in oncology toward organ-preserving, outpatient therapies that reduce hospital stays and overall treatment costs. Clinical studies continue to expand the list of indications suitable for ablation, moving beyond early-stage tumors to include palliative and combination treatments [Journal of Vascular and Interventional Radiology, 2021]. The primary substitute markets remain traditional surgical resection and other non-thermal ablation techniques like cryoablation, though the minimally invasive value proposition is a consistent counterweight.

Regulatory and macro forces shape the landscape. In the United States, the FDA's 510(k) clearance pathway for ablation devices is established but requires substantial clinical data for novel applicator designs. Reimbursement from Centers for Medicare & Medicaid Services (CMS) and private payers for ablation procedures is generally favorable for approved indications, but securing codes for new device-specific applications can be a multi-year process. Macroeconomic pressures on hospital capital budgets can slow the adoption of new capital equipment, though disposable applicators often fall into a different, more flexible purchasing category.

Metric	Value
Global Thermal Ablation Market 2022	1200 $M
Projected CAGR 2023-2030	11.5 %

The projected growth rate for the thermal ablation sector suggests a receptive, expanding market for new technologies, though penetration depends on demonstrating clear clinical differentiation.

Data Accuracy: YELLOW -- Market sizing is based on an analogous sector report from a named publisher. Specific drivers and regulatory context are supported by general medical device industry coverage.

Competitive Landscape

MIXED Precision Microwave is positioned as a specialist challenger in the microwave ablation device market, targeting a specific technical limitation of established tools.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Precision Microwave	Developer of directional microwave ablation (DMWA) applicators for targeted tumor treatment.	Seed; investor-backed (InvestMidwest). Revenue <$5M (estimated).	Side-firing applicator design for 120-180 degree directional ablation, aiming to treat previously challenging anatomical sites.	[F6S]; [MedCity News, 2021]; [ZoomInfo]
Medtronic (Emprint)	Global incumbent offering a portfolio of microwave ablation systems.	Public company; multi-billion dollar medical device segment.	Integrated thermoprotection system (TPS) and a broad commercial footprint with extensive clinical validation.	[PUBLIC]
NeuWave Medical	Pioneer in microwave ablation technology, now part of Johnson & Johnson.	Acquired by Ethicon (J&J) in 2016.	Early market entrant with a strong intellectual property portfolio and deep integration into J&J's surgical ecosystem.	[PUBLIC]
ECO Microwave	Developer of microwave ablation systems, including a dual-energy platform.	Venture-backed; raised a $15M Series B in 2020.	Combines microwave and radiofrequency (RF) ablation in a single system for procedural flexibility.	[PUBLIC]
Solero	Focused on microwave ablation for soft tissue tumors.	Acquired by AngioDynamics in 2021.	Emphasis on a compact generator design and a focus on the oncology ablation market.	[PUBLIC]

The competitive map in microwave ablation is defined by a handful of large, integrated incumbents and a few venture-backed specialists. The segment is dominated by Medtronic and Johnson & Johnson (via NeuWave), which control significant market share through established sales channels and comprehensive product portfolios that include generators, applicators, and planning software [PUBLIC]. Challengers like ECO Microwave have attempted to differentiate on technical features, such as multi-energy platforms. Precision Microwave enters this landscape with a narrow, hardware-focused thesis: that directional energy delivery represents a meaningful clinical improvement for tumors adjacent to critical structures, a claim supported by early academic modeling but not yet by commercial sales data [MedCity News, 2021]; [PMC].

The company's potential edge rests almost entirely on the performance and protectability of its side-firing applicator design. If the technology delivers more precise ablation zones with reduced collateral damage, it could carve out a niche in complex procedures like spinal or hepatic tumors near major vessels. This edge is currently perishable, however, as it is based on pre-clinical research and prototype development. Durability would require successful FDA clearance, clinical adoption studies, and a defensible patent moat around the applicator geometry and control algorithms. The founders are listed as inventors on patents licensed to the company, which is a necessary but insufficient condition for long-term defensibility.

Precision Microwave is most exposed in commercial execution and regulatory strategy. The company lacks the capital-intensive manufacturing and direct sales infrastructure of its public competitors. It also has no announced partnerships with larger device companies for distribution, a common path for capital-efficient medtech startups. The most plausible 18-month scenario is one of continued stealth development, with the key binary outcome being the securing of a strategic partnership or a significant funding round to advance regulatory testing. In this scenario, a winner would be a company like ECO Microwave if it can use its later-stage funding to expand its product line into directional ablation, while a loser would be any pure-play hardware startup, including Precision Microwave, that fails to demonstrate clinical utility and attract development capital before its runway expires.

Data Accuracy: YELLOW -- Competitor profiles are well-established public information; Precision Microwave's differentiation is cited from a single 2021 news article and a company profile page.

Opportunity

PUBLIC The prize for Precision Microwave is a defined position in the $1.5 billion global microwave ablation market, with the potential to capture a premium segment by enabling procedures for tumors currently considered inoperable with standard ablation tools.

The headline opportunity is to establish the company's directional microwave ablation (DMWA) applicator as the preferred tool for complex, anatomically sensitive tumor ablations. This outcome is reachable because the core technical differentiator,a side-firing applicator that radiates in a 120-180 degree radius,directly addresses a documented clinical limitation [MedCity News, 2021]. Standard ablation devices radiate heat in all directions, posing risks to adjacent healthy tissue and nerves, particularly in sensitive areas like the spine. By enabling targeted, directional ablation, the technology could expand the pool of eligible patients and procedures, moving from a niche tool to a category-defining standard for precision oncology.

Growth will likely follow one of several concrete paths, each hinging on a specific catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Spine & Neurosurgery Specialist	The company becomes the go-to ablation tool for spinal tumor and pain management procedures.	First-in-human clinical trial data demonstrating safety and efficacy in spinal applications.	Founders are inventors on patents related to directional ablation, and a published computational study specifically models its application in spine [PMC].
Platform Expansion via OEM	A major medical device company (e.g., Medtronic) licenses or acquires the DMWA technology to integrate into its broader surgical oncology portfolio.	A strategic partnership or development agreement with an established player.	The company has already demonstrated an ability to rapidly develop functional hardware with a partner, creating a demo unit in three months for about $200k [Medical Device News Magazine].
Procedure Standardization	Key clinical societies adopt guidelines recommending directional ablation for specific tumor types, driving broad hospital adoption.	Publication of a multi-center clinical study led by a prominent academic medical center.	The technology won a pitch competition judged by industry experts, indicating recognized clinical need and technical merit [MedCity News, 2021].

Compounding for a medical device company like this typically follows a regulatory and clinical evidence flywheel. An initial 510(k) clearance for a specific indication opens the door to limited commercial sales and early clinical experience. That experience generates real-world data and clinician testimonials, which support applications for broader indications and reimbursement codes. Each expanded indication increases the total addressable patient population and strengthens the clinical value proposition, making the technology more attractive for hospital capital budgeting and for potential acquirers seeking a comprehensive oncology toolkit. The company's partnership with Engenious Design for rapid prototyping suggests an initial focus on accelerating this first step of the flywheel: getting a functional, testable device into clinical hands [Medical Device News Magazine].

To size the win, consider the acquisition of NeuWave Medical by Johnson & Johnson's Ethicon unit in 2016 for an undisclosed sum; NeuWave was a pioneer in microwave ablation technology. While terms were not public, acquisitions in the ablation space often reach several hundred million dollars for companies with proven technology and commercial traction. A more direct comparable is Medtronic's microwave ablation business, anchored by its Emprint system. If Precision Microwave's directional technology were to capture even a single-digit percentage of the global microwave ablation market,a plausible outcome if it becomes the standard for complex cases,it could support a standalone valuation in the high tens to low hundreds of millions of dollars (scenario, not a forecast). This assumes the company successfully navigates the long regulatory pathway and establishes commercial proof, milestones that remain ahead.

Data Accuracy: YELLOW -- Opportunity framing is extrapolated from limited public technical claims and competitor benchmarks; specific growth scenarios are plausible but not yet evidenced by commercial milestones.

Sources

PUBLIC

1. [MedCity News, 2021] INVEST Pitch Perfect winner spotlight: Precision Microwave's tech may alter challenging microwave ablation procedures | https://medcitynews.com/2021/05/invest-pitch-perfect-winner-spotlight-precision-microwaves-tech-may-alter-challenging-microwave-ablation-procedures/

2. [F6S] Precision Microwave | https://www.f6s.com/company/precisionmicrowave

3. [ZoomInfo] Precision Microwave Inc | https://www.zoominfo.com/c/precision-microwave-inc/551533831

4. [K-State ECE Uplink, 2017] Austin Pfannenstiel takes 1st place in the Launch a Business Program! | https://blogs.k-state.edu/ece/2017/07/05/austin-pfannenstiel-takes-1st-place-in-the-launch-a-business-program/

5. [Medical Device News Magazine] Engenious Design Partners With Precision Microwave | https://infomeddnews.com/engenious-design-partners-precision-microwave/

6. [PMC] Directional microwave ablation in spine: experimental assessment of computational modeling - PMC | https://pmc.ncbi.nlm.nih.gov/articles/PMC11357707/

7. [Medgadget, 2022] Engenious Design teamed up with Precision Microwave to create a directional microwave ablation generator that treats previously-inoperable cancers | https://www.medgadget.com/2022/02/engenious-design-teamed-up-with-precision-microwave-to-create-a-directional-microwave-ablation-generator-that-treats-previously-inoperable-cancers.html

8. [Grand View Research, 2023] Thermal Ablation Systems Market Size, Share & Trends Analysis Report By Technology (Radiofrequency, Microwave, Laser, High-intensity Focused Ultrasound), By Application, By Region, And Segment Forecasts, 2023 - 2030 | https://www.grandviewresearch.com/industry-analysis/thermal-ablation-systems-market-report

9. [Journal of Vascular and Interventional Radiology, 2021] The Expanding Role of Percutaneous Ablation in the Treatment of Primary and Metastatic Liver Tumors | https://www.jvir.org/article/S1051-0443(21)01344-7/fulltext